🚀 VC round data is live in beta, check it out!
Aardvark Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aardvark Therapeutics and similar public comparables like InflaRx, Coya Therapeutics, Bioxyne, Assertio Therapeutics and more.
Aardvark Therapeutics Overview
About Aardvark Therapeutics
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Founded
2017
HQ
Employees
22
Website
Sectors
Financials (LTM)
EV
$5M
Aardvark Therapeutics Financials
Aardvark Therapeutics reported last 12-month revenue of — and negative EBITDA of ($62M).
In the same LTM period, Aardvark Therapeutics generated — in gross profit, ($62M) in EBITDA losses, and had net loss of ($63M).
Revenue (LTM)
Aardvark Therapeutics P&L
In the most recent fiscal year, Aardvark Therapeutics reported revenue of — and EBITDA of ($58M).
Aardvark Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($62M) | XXX | ($58M) | XXX | XXX | XXX |
| Net Profit | ($63M) | XXX | ($58M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aardvark Therapeutics Stock Performance
Aardvark Therapeutics has current market cap of $114M, and enterprise value of $5M.
Market Cap Evolution
Aardvark Therapeutics' stock price is $5.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5M | $114M | 0.0% | XXX | XXX | XXX | $-2.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAardvark Therapeutics Valuation Multiples
Aardvark Therapeutics trades at (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Aardvark Therapeutics Financial Valuation Multiples
As of April 19, 2026, Aardvark Therapeutics has market cap of $114M and EV of $5M.
Equity research analysts estimate Aardvark Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aardvark Therapeutics has a P/E ratio of (1.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $114M | XXX | $114M | XXX | XXX | XXX |
| EV (current) | $5M | XXX | $5M | XXX | XXX | XXX |
| EV/EBITDA | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| P/E | (1.8x) | XXX | (2.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aardvark Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aardvark Therapeutics Margins & Growth Rates
Aardvark Therapeutics' revenue in the last fiscal year grew by —.
Aardvark Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.9M for the same period.
Aardvark Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 23% | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aardvark Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aardvark Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| InflaRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Coya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioxyne | XXX | XXX | XXX | XXX | XXX | XXX |
| Assertio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Faron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aardvark Therapeutics M&A Activity
Aardvark Therapeutics acquired XXX companies to date.
Last acquisition by Aardvark Therapeutics was on XXXXXXXX, XXXXX. Aardvark Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aardvark Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAardvark Therapeutics Investment Activity
Aardvark Therapeutics invested in XXX companies to date.
Aardvark Therapeutics made its latest investment on XXXXXXXX, XXXXX. Aardvark Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aardvark Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aardvark Therapeutics
| When was Aardvark Therapeutics founded? | Aardvark Therapeutics was founded in 2017. |
| Where is Aardvark Therapeutics headquartered? | Aardvark Therapeutics is headquartered in United States. |
| How many employees does Aardvark Therapeutics have? | As of today, Aardvark Therapeutics has over 22 employees. |
| Who is the CEO of Aardvark Therapeutics? | Aardvark Therapeutics' CEO is Bryan Jones. |
| Is Aardvark Therapeutics publicly listed? | Yes, Aardvark Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Aardvark Therapeutics? | Aardvark Therapeutics trades under AARD ticker. |
| When did Aardvark Therapeutics go public? | Aardvark Therapeutics went public in 2025. |
| Who are competitors of Aardvark Therapeutics? | Aardvark Therapeutics main competitors are InflaRx, Coya Therapeutics, Bioxyne, Assertio Therapeutics. |
| What is the current market cap of Aardvark Therapeutics? | Aardvark Therapeutics' current market cap is $114M. |
| Is Aardvark Therapeutics profitable? | No, Aardvark Therapeutics is not profitable. |
| What is the current EBITDA of Aardvark Therapeutics? | Aardvark Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Aardvark Therapeutics? | Current EBITDA multiple of Aardvark Therapeutics is (0.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.